

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT UPDATE ON CO-DEVELOPMENT OF NEW DRUG

Reference is made to the voluntary announcement of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 29 May 2017 in relation to co-development of KLT-1101, a new biological drug that was co-developed by Kanglilai and the Group as its contract research service provider (“**Co-Development Project on New Drug**”). Capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement.

The Board was informed by Kanglilai that on 25 October 2017, Kanglilai was formally informed by CFDA of its approval on clinical trial and was approved to commence clinical studies of KLT-1101 on “chemoradiotherapy-induced leukopenia and thrombocytopenia for tumor treatment”.

KLT-1101 is a kind of recombinant human cytokine proteins, which demonstrates positive signs of treatment effects in the complete recovery of hemogram, suppression of tumor cell proliferation, improvement in immunity of patients, etc. Subject to the further approval of CFDA after the completion of the clinical trial and launching the drug to the market, KLT-1101 can ameliorate the negative situation of patients’ inability to complete their treatment cycle or even mortality caused by weakened blood production due to chemoradiotherapy. Meanwhile, the drug could efficiently prevent, relieve and treat radiation damage to the human body. It is believed that KLT-1101 could also serve as a backup drug for nuclear emergency and help enhance the national standard of responsive measures on the prevention of nuclear emergency.

The Group believes that the encouraging achievement of the Co-Development Project on New Drug demonstrates the technological strengths of the Group in drug research and development.

By order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 25 October 2017

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan, Mr. HUANG Zuie-Chin and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian and Ms. ZHANG Min.

** For identification purposes only*